KRTL Biotech Highlights ELIXIR as Flagship Hydration Product in Bolivia
MWN-AI** Summary
KRTL Holding Group Inc. (OTC: KRTL) is significantly positioning its subsidiary, KRTL Biotech, Inc. and its flagship product, ELIXIR, in the Bolivian market as a premier hydration solution. Announced on October 2, 2025, ELIXIR is a high-performance electrolyte beverage crafted under stringent GMP-compliant conditions at KRTL's Bolivian facility. Designed to combat dehydration from physical exertion, heat, or alcohol, it boasts a proprietary formula enriched with essential electrolytes like sodium, potassium, calcium, magnesium, and glucose.
Notably, ELIXIR has found traction in more than 7,000 retail locations across Bolivia, ranging from drugstores to supermarkets. Its versatility has garnered it a dual reputation as a go-to hangover recovery aid and a refreshing mixer for cocktails, firmly establishing it in nightclubs, gyms, and homes alike. The vibrant branding and cultural relevance have elevated ELIXIR to a household name, as highlighted by KRTL's CEO, Cesar Herrera.
With product offerings that include a diverse flavor lineup and packaging options, ELIXIR is strategically crafted for various consumer needs. Moving forward, KRTL Biotech is eyeing international expansion, particularly into the U.S. market, which presents lucrative opportunities for hydration and functional wellness beverages. The company is currently navigating the regulatory landscape to ensure compliance with FDA requirements while developing a robust market strategy to facilitate a smooth entry into the global market.
Both KRTL Biotech and SIGMA, a seasoned Bolivian pharmaceutical manufacturer, are committed to driving innovation and maintaining high-quality standards as they leverage ELIXIR’s success for potential global scaling.
MWN-AI** Analysis
KRTL Biotech's recent emphasis on ELIXIR as its flagship hydration product in Bolivia reflects both an astute recognition of market dynamics and a well-planned expansion strategy. The hydration beverage sector is witnessing unprecedented growth, particularly among health-conscious consumers, making ELIXIR—formulated to efficiently replenish essential electrolytes—uniquely positioned for success.
With over 7,000 retail locations in Bolivia, ELIXIR’s penetration enhances brand visibility. Its broad appeal, not just as a sport recovery drink but also a hangover aid and mixer, demonstrates its versatility, catering to diverse consumer needs. As KRTL Biotech prepares for international market entry, including an assessment of U.S. regulatory compliance, the company's proactive approach to packaging and health claims suggests readiness for scalability.
Investors should note the evolving landscape of functional wellness beverages, where demand for effective hydration solutions continues to surge. The proprietary formulation of ELIXIR, combining essential electrolytes and innovative flavors, positions it competitively against traditional sports drinks. Additionally, the partnership with SIGMA—a well-established pharmaceutical manufacturer in Bolivia—boosts credibility and operational capacity, setting a precedent for potential future acquisitions or collaborations in other markets.
As KRTL Biotech aligns its strategy for the U.S. market entry, the company could leverage branding, focusing on the increasing consumer trend toward wellness products and recovery aids. Given that the U.S. hydration beverage market is on an upward trajectory, KRTL Holdings stands to benefit significantly from ELIXIR's global rollout.
Potential investors should closely monitor KRTL Holdings for further updates on their regulatory progress in the U.S., as successful market entry could exponentially raise the company's valuation. With a solid foundation in Bolivia and a clear pathway for expansion, KRTL’s ELIXIR may well prove to be a lucrative investment opportunity in the burgeoning health beverage sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lakewood, CO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting ELIXIR, a high-performance electrolyte hydration beverage, as one of its most commercially successful and strategically positioned consumer health products in the Bolivian Market
Produced under GMP-compliant conditions at KRTL Biotech’s Bolivian facility, ELIXIR is a non-alcoholic, hypertonic hydration beverage designed to rapidly restore essential electrolytes and combat dehydration caused by intense physical activity, heat exposure, or alcohol consumption. With a proprietary formula containing glucose, sodium, potassium, calcium, magnesium, and citric acid, ELIXIR is scientifically formulated to hydrate cells more efficiently than traditional sports drinks.
Currently available in more than 7,000 retail drugstores, major supermarkets, and club stores throughout Bolivia, ELIXIR has earned a reputation as both a hangover recovery essential and a popular mixer in cocktails. Its vibrant branding and broad consumer appeal have made it a mainstay in nightclubs, gyms, and family households alike.
"ELIXIR represents the intersection of scientific hydration and lifestyle relevance," said Cesar Herrera, CEO of KRTL Holding Group Inc. "It’s not only a formulation rooted in health science but also a brand with a strong cultural footprint in Bolivia and a compelling case for expansion."
The ELIXIR lineup includes flavors such as Berry, Arándano, Citrus Punch, Tropical Flavor, Mango Zero (no sugar), and Electro Mandarina in sachet format. The variety of packaging—from single-serve sachets to sleek 625ml bottles—makes ELIXIR suitable for retail shelves, on-the-go consumption, and hospitality applications.
KRTL Biotech is preparing to initiate structured pathways for international market introduction, including regulatory entry into the United States. The U.S. market for hydration solutions, functional wellness beverages, and alcohol recovery aids continues to expand, offering strong demand signals for ELIXIR's unique formulation and branding. As part of this strategy, KRTL Biotech is assessing packaging compliance, ingredient disclosures, and permissible health claims to align with FDA labeling requirements. In parallel, the Company is also developing an import framework and market positioning strategy to support commercial rollout once regulatory alignment is complete.
"As a company rooted in both science and innovation, we’re proud to see ELIXIR emerge as a household name in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "Its evolution from a pharmaceutical concept to a cultural staple represents exactly the kind of product innovation we aim to scale globally."
"We see ELIXIR as more than a product—it’s a proven platform for wellness and recovery," said Daniel Bishop, CEO of KRTL Biotech. "With real-world adoption and scalable production already in place, it offers us a clear path to enter functional beverage markets globally."
For more on ELIXIR, visit the brand's Instagram at @elixir.bo or follow them on Facebook at facebook.com/elixir .
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
www.krtlholding.cominfo@krtlholding.comwww.krtlbiotech.cominfo@krtlbiotech.comwww.krtl-icc.cominfo@krtl-icc.com
FAQ**
How does KRTL Holding Group Inc KRTL plan to address the regulatory challenges when entering the U.S. market for their ELIXIR beverage, particularly regarding ingredient disclosures and health claims?
What specific strategies is KRTL Holding Group Inc KRTL employing to maintain its competitive edge in the rapidly expanding U.S. hydration solutions market?
How does KRTL Holding Group Inc KRTL intend to scale the distribution of ELIXIR beyond Bolivia, and what markets are they considering for international expansion?
What has been the consumer response to ELIXIR in Bolivia, and how does KRTL Holding Group Inc KRTL plan to leverage this feedback to enhance their marketing strategies for the U.S. rollout?
**MWN-AI FAQ is based on asking OpenAI questions about KRTL Holding Group Inc (OTC: KRTL).
NASDAQ: KRTL
KRTL Trading
16.0% G/L:
$0.0464 Last:
31,400 Volume:
$0.035 Open:
